TMPO antisense RNA 1 (TMPO-AS1)

TMPO antisense RNA 1 (TMPO-AS1) is a long non-coding RNA (>200 nucleotides) transcribed from the antisense strand of the TMPO gene and functions as a key regulator in the progression of several human cancers. TMPO-AS1 exerts its oncogenic effects by acting as a competing endogenous RNA, sponging tumor-suppressive microRNAs and releasing inhibition of tumor-promoting genes, thereby increasing cell proliferation, migration, invasion, and promoting epithelial–mesenchymal transition (EMT)[1][2][3][4]. Recent studies demonstrate that TMPO-AS1 can function as a molecular scaffold to enhance signaling pathways (e.g., Wnt/β-catenin signaling in bone metastatic prostate cancer[3]), and modulate transcriptional activity of downstream effectors (e.g., LCN2 via E2F6 in breast cancer[5]). TMPO-AS1 expression is strongly upregulated in various tumor types compared to normal tissues and is associated with poor prognosis and aggressive clinical features[1][2][3][4]. TMPO-AS1 currently represents a novel and promising therapeutic target and biomarker for cancer diagnosis and prognosis, though no approved drugs targeting TMPO-AS1 are available at this time.

Other names

TMPO antisense RNA 1 (non-protein coding)TMPO-AS1

Sponging specific tumor suppressor microRNAs (e.g., miR-140-5p in breast cancer, miR-126-3p in hepatocellular carcinoma, miR-383-5p in pancreatic cancer) - Enhancing the expression of tumor-promoting genes (e.g., SOX11 in pancreatic cancer via miR-383-5p, LRP6 in HCC via miR-126-3p) - Scaffold for signaling proteins, enhancing Wnt/β-catenin pathway activity in prostate cancer - Promoting transcriptional activity of LCN2 via interaction with transcription factor E2F6